Loading clinical trials...
Loading clinical trials...
A Phase 1b With Expansion Study Evaluating the Efficacy and Safety of Momelotinib Combined With Trametinib in Subjects With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
Conditions
Interventions
Momelotinib (MMB)
Trametinib
Locations
5
United States
Duarte, California, United States
Sacramento, California, United States
Boston, Massachusetts, United States
Fairfax, Virginia, United States
Spokane, Washington, United States
Start Date
March 11, 2015
Primary Completion Date
July 19, 2016
Completion Date
February 27, 2017
Last Updated
February 1, 2019
Lead Sponsor
Sierra Oncology LLC - a GSK company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions